Literature DB >> 31922471

Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis.

Yuko Ota1, Masataka Kuwana1.   

Abstract

Systemic sclerosis (SSc) is a connective tissue disease characterized by excessive fibrosis, microvasculopathy, and autoimmunity. Endothelial cell (EC) injury and subsequent endothelial cell dysfunction is believed to be an initial event that eventually leads to a vicious pathogenic cycle. This process is further enhanced by defective angiogenesis and vasculogenesis, as the vascular repair machinery does not work properly. Endothelial progenitor cells (EPCs) are functionally and quantitatively insufficient to recover the endothelium in SSc patients. The dysfunctional ECs and EPCs not only trigger the formation of typical vascular lesions, such as progressive intimal fibrosis in small arteries and the loss of capillaries, but also promote a series of inflammatory and profibrotic processes, such as endothelial-mesenchymal transition and recruitment and accumulation of monocytic EPCs with profibrotic properties. These processes together contribute to the accumulation of extracellular matrix in the affected tissue. This review features current insights into the roles of ECs and EPCs in the pathogenesis of SSc.

Entities:  

Year:  2019        PMID: 31922471     DOI: 10.5152/eurjrheum.2019.19158

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  7 in total

1.  Altered Properties of Endothelial Cells and Mesenchymal Stem Cells Underlying the Development of Scleroderma-like Vasculopathy in KLF5+/- ;Fli-1+/- Mice.

Authors:  Kouki Nakamura; Takashi Taniguchi; Megumi Hirabayashi; Takashi Yamashita; Ryosuke Saigusa; Shunsuke Miura; Takehiro Takahashi; Tetsuo Toyama; Yohei Ichimura; Ayumi Yoshizaki; Maria Trojanowska; Katsuhito Fujiu; Ryozo Nagai; Shinichi Sato; Yoshihide Asano
Journal:  Arthritis Rheumatol       Date:  2020-10-30       Impact factor: 10.995

2.  Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis.

Authors:  Dipanjan Bhattacharjee; Sumantro Mondal; Ayindrila Saha; Sanchaita Misra; Sudipta Chatterjee; Ankur Rao; Avik Sarkar; Sulagna Chatterjee; Pradyot Sinhamahapatra; Alakendu Ghosh
Journal:  Clin Exp Med       Date:  2022-06-25       Impact factor: 3.984

Review 3.  Endothelial-to-mesenchymal transition in systemic sclerosis.

Authors:  P Cipriani; R Giacomelli; P Di Benedetto; P Ruscitti; O Berardicurti; M Vomero; L Navarini; V Dolo
Journal:  Clin Exp Immunol       Date:  2021-04-18       Impact factor: 5.732

4.  Hypoxia-induced interstitial transformation of microvascular endothelial cells by mediating HIF-1α/VEGF signaling in systemic sclerosis.

Authors:  Jing Mao; Jiexiong Liu; Mei Zhou; Guiqiang Wang; Xia Xiong; Yongqiong Deng
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

Review 5.  Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.

Authors:  Liala Moschetti; Silvia Piantoni; Enrico Vizzardi; Edoardo Sciatti; Mauro Riccardi; Franco Franceschini; Ilaria Cavazzana
Journal:  Front Med (Lausanne)       Date:  2022-04-08

6.  Circulating Neurovascular Guidance Molecules and Their Relationship with Peripheral Microvascular Impairment in Systemic Sclerosis.

Authors:  Eloisa Romano; Irene Rosa; Bianca Saveria Fioretto; Marco Matucci-Cerinic; Mirko Manetti
Journal:  Life (Basel)       Date:  2022-07-14

Review 7.  Promising Strategies for Preserving Adult Endothelium Health and Reversing Its Dysfunction: From Liquid Biopsy to New Omics Technologies and Noninvasive Circulating Biomarkers.

Authors:  Carmela Rita Balistreri
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.